行情

LCTX

LCTX

Lineage Cell Therapeutics Inc
AMEX

实时行情|Nasdaq Last Sale

0.7201
-0.0437
-5.72%
盘后: 0.8500 +0.1299 +18.04% 19:54 04/03 EDT
开盘
0.7500
昨收
0.7638
最高
0.7767
最低
0.7000
成交量
54.16万
成交额
--
52周最高
1.670
52周最低
0.5339
市值
1.08亿
市盈率(TTM)
-15.9667
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测LCTX价格均价为4.250,最高价位6.00,最低价为3.000。

EPS

LCTX 新闻

更多
  • 欧佩克+会议推迟 沙特与俄罗斯紧张局势升级 周一油价料将暴跌
  • 新浪美股 · 3小时前
  • 迪拜将人员流动限制措施扩大至24小时限制
  • 新浪美股 · 4小时前
  • 特朗普称将申请更多中小企业纾困资金
  • 央视 · 5小时前
  • 美加联合施压促减产 考虑对沙特和俄罗斯石油征税
  • 新浪美股 · 5小时前

所属板块

生物技术和医学研究
-0.50%
制药与医学研究
-0.22%

热门股票

代码
价格
涨跌幅

LCTX 简况

Lineage Cell Therapeutics, Inc., formerly BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Company is focused on developing cell therapies. It programs are based on its cell-based therapy platform. It is focused on developing treatments for conditions, including age-related degenerative diseases and other serious medical conditions. Its pipeline includes OpRegen, OPC1 and VAC2. OpRegen product candidate is a cell replacement therapy. OpRegen is comprised of retinal pigment epithelium cells and is being tested for the treatment of advanced dry age-related macular degeneration (dry AMD) with geographic atrophy. OPC1 is a cell replacement therapy comprised of oligodendrocyte progenitor cells. OPC1 is being developed for the treatment of acute spinal cord injuries (SCI). VAC2 is an allogeneic cancer immunotherapy comprised of mature, antigen-presenting dendritic cells. VAC2 is being developed for non-small cell lung cancer (NSCLC).
展开

微牛提供Lineage Cell Therapeutics Inc(AMEX-LCTX)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的LCTX股票新闻,以帮助您做出投资决策。